The basic aim of this work was to examine possibilities for introducing a new biotechnological treatment for preparation, storage and further purifying the suspension of leukocytes ("buffy coat" (BC)), intended for production of human interferon-alpha (hIFN-hIFN-α) and human interferon-gamma (hIFN-γ). Three hundred and eighty four units of BC were examined. They were divided into three series of 128 BC units each - one control series (KSBC) and two experimental series to which 10% dextran solution (ESBC-I) or 6% hydroxyethyl starch solution (ESBC-II) were added. The lowest titer (297929 IU) of hIFN-α ensued from KSBC, a higher titer from ESBC-I (317184 IU) and the highest titer from ESBC-II (364406 IU). We also found that the lowest hIFN- γ titer was produced from KSBC (48142 IU), a somewhat larger one from ESBC-I (67571 IU), and the highest titer was obtained from ESBC-II (73428. IU). This study has demonstrated the positive influence of modified biotechnological treatments on the production of hIFN-α and hIFN- γ from BC
